Global Pericarditis Drugs Market 2019-2023
SKU ID : TNV-14326706 | Publishing Date : 21-May-2019 | No. of pages : 128
Detailed TOC of Global Pericarditis Drugs Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
Market segmentation by product
Comparison by product
NSAIDs - Market size and forecast 2018-2023
Colchicine - Market size and forecast 2018-2023
Others - Market size and forecast 2018-2023
Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
AstraZeneca Plc
Bayer AG
Johnson & Johnson Services Inc.
Pfizer Inc.
Takeda Pharmaceutical Co. Ltd.
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global cardiovascular disorder treatment market
Exhibit 02: Segments of global cardiovascular disorder treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Emerging trends in global pericarditis drugs market
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Market overview 2018
Exhibit 10: Analysis of global pericarditis drugs market 2018
Exhibit 11: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 12: Five forces analysis 2018
Exhibit 13: Five forces analysis 2023
Exhibit 14: Bargaining power of buyers
Exhibit 15: Bargaining power of suppliers
Exhibit 16: Threat of new entrants
Exhibit 17: Threat of substitutes
Exhibit 18: Threat of rivalry
Exhibit 19: Market condition - Five forces 2018
Exhibit 20: Product - Market share 2018-2023 (%)
Exhibit 21: Comparison by product
Exhibit 22: NSAIDs - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Treatment regime with NSAIDS for pericarditis
Exhibit 24: NSAIDs - Year-over-year growth 2019-2023 (%)
Exhibit 25: Colchicine - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Colchicine - Year-over-year growth 2019-2023 (%)
Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Others - Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by product
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Centers for Disease Control and Prevention (CDC) facts about heart disease
Exhibit 35: North America - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in North America
Exhibit 37: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Europe
Exhibit 40: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in Asia
Exhibit 43: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 44: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 45: Top 3 countries in ROW
Exhibit 46: Key leading countries
Exhibit 47: Market opportunity
Exhibit 48: Side effects associated with use of NSAIDs
Exhibit 49: Renal impairment associated with use of NSAIDs
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Geriatric population scenario in US 2017
Exhibit 52: Vendor landscape
Exhibit 53: Landscape disruption
Exhibit 54: Vendors covered
Exhibit 55: Vendor classification
Exhibit 56: Market positioning of vendors
Exhibit 57: AstraZeneca Plc - Vendor overview
Exhibit 58: AstraZeneca Plc - Product segments
Exhibit 59: AstraZeneca Plc - Organizational developments
Exhibit 60: AstraZeneca Plc - Geographic focus
Exhibit 61: AstraZeneca Plc - Key offerings
Exhibit 62: AstraZeneca Plc - Key customers
Exhibit 63: Bayer AG - Vendor overview
Exhibit 64: Bayer AG - Product segments
Exhibit 65: Bayer AG - Organizational developments
Exhibit 66: Bayer AG - Geographic focus
Exhibit 67: Bayer AG - Segment focus
Exhibit 68: Bayer AG - Key offerings
Exhibit 69: Bayer AG - Key customers
Exhibit 70: Johnson & Johnson Service, Inc. - Vendor overview
Exhibit 71: Johnson & Johnson Services, Inc. - Business segments
Exhibit 72: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 73: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 74: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 75: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 76: Johnson & Johnson Services, Inc. - Key customers
Exhibit 77: Pfizer Inc. - Vendor overview
Exhibit 78: Pfizer Inc. - Business segments
Exhibit 79: Pfizer Inc. - Organizational developments
Exhibit 80: Pfizer Inc. - Geographic focus
Exhibit 81: Pfizer Inc. - Segment focus
Exhibit 82: Pfizer Inc. - Key offerings
Exhibit 83: Pfizer Inc. - Key customers
Exhibit 84: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 85: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 86: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 87: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 88: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 89: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 90: Validation techniques employed for market sizing
Exhibit 91: Definition of market positioning of vendors
Keyplayers in Global Pericarditis Drugs Market 2019-2023
AstraZeneca PlcBayer AG
Johnson & Johnson Services Inc.
Pfizer Inc.
Takeda Pharmaceutical Co. Ltd.